214 related articles for article (PubMed ID: 28646022)
1. NF1
Dodd RD; Lee CL; Overton T; Huang W; Eward WC; Luo L; Ma Y; Ingram DR; Torres KE; Cardona DM; Lazar AJ; Kirsch DG
Cancer Res; 2017 Aug; 77(16):4486-4497. PubMed ID: 28646022
[TBL] [Abstract][Full Text] [Related]
2. NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition.
Dodd RD; Mito JK; Eward WC; Chitalia R; Sachdeva M; Ma Y; Barretina J; Dodd L; Kirsch DG
Mol Cancer Ther; 2013 Sep; 12(9):1906-17. PubMed ID: 23858101
[TBL] [Abstract][Full Text] [Related]
3. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors.
LaFemina J; Qin LX; Moraco NH; Antonescu CR; Fields RC; Crago AM; Brennan MF; Singer S
Ann Surg Oncol; 2013 Jan; 20(1):66-72. PubMed ID: 22878618
[TBL] [Abstract][Full Text] [Related]
4. Genomic Status of
Peacock JD; Pridgeon MG; Tovar EA; Essenburg CJ; Bowman M; Madaj Z; Koeman J; Boguslawski EA; Grit J; Dodd RD; Khachaturov V; Cardona DM; Chen M; Kirsch DG; Maina F; Dono R; Winn ME; Graveel CR; Steensma MR
Cancer Res; 2018 Jul; 78(13):3672-3687. PubMed ID: 29720369
[TBL] [Abstract][Full Text] [Related]
5. Clinical signs of neurofibromatosis impact on the outcome of malignant peripheral nerve sheath tumors.
Lamm W; Schur S; Köstler WJ; Funovics P; Windhager R; Amann G; Panotopoulos J; Pokrajac B; Brodowicz T
Oncology; 2014; 86(2):122-6. PubMed ID: 24480823
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1.
Fang Y; Elahi A; Denley RC; Rao PH; Brennan MF; Jhanwar SC
Anticancer Res; 2009 Apr; 29(4):1255-62. PubMed ID: 19414372
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner.
Byer SJ; Eckert JM; Brossier NM; Clodfelder-Miller BJ; Turk AN; Carroll AJ; Kappes JC; Zinn KR; Prasain JK; Carroll SL
Neuro Oncol; 2011 Jan; 13(1):28-41. PubMed ID: 21075781
[TBL] [Abstract][Full Text] [Related]
8. Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors: II. The role of dysregulated growth factor signaling.
Carroll SL; Stonecypher MS
J Neuropathol Exp Neurol; 2005 Jan; 64(1):1-9. PubMed ID: 15715079
[TBL] [Abstract][Full Text] [Related]
9. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
[TBL] [Abstract][Full Text] [Related]
10. Mouse models of tumor development in neurofibromatosis type 1.
Cichowski K; Shih TS; Schmitt E; Santiago S; Reilly K; McLaughlin ME; Bronson RT; Jacks T
Science; 1999 Dec; 286(5447):2172-6. PubMed ID: 10591652
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS.
Reuss DE; Mucha J; Hagenlocher C; Ehemann V; Kluwe L; Mautner V; von Deimling A
PLoS One; 2013; 8(2):e57152. PubMed ID: 23437333
[TBL] [Abstract][Full Text] [Related]
12. Genetic basis of tumorigenesis in NF1 malignant peripheral nerve sheath tumors.
Upadhyaya M
Front Biosci (Landmark Ed); 2011 Jan; 16(3):937-51. PubMed ID: 21196210
[TBL] [Abstract][Full Text] [Related]
13. Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings.
Spurlock G; Knight SJ; Thomas N; Kiehl TR; Guha A; Upadhyaya M
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1869-80. PubMed ID: 20229272
[TBL] [Abstract][Full Text] [Related]
14. Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors.
Hagel C; Zils U; Peiper M; Kluwe L; Gotthard S; Friedrich RE; Zurakowski D; von Deimling A; Mautner VF
J Neurooncol; 2007 Apr; 82(2):187-92. PubMed ID: 17111191
[TBL] [Abstract][Full Text] [Related]
15. Different sized somatic NF1 locus rearrangements in neurofibromatosis 1-associated malignant peripheral nerve sheath tumors.
Pasmant E; Vidaud D; Harrison M; Upadhyaya M
J Neurooncol; 2011 May; 102(3):341-6. PubMed ID: 20686819
[TBL] [Abstract][Full Text] [Related]
16. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.
Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE
J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165
[TBL] [Abstract][Full Text] [Related]
17. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH
Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628
[TBL] [Abstract][Full Text] [Related]
18. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
19. An orthotopic xenograft model of intraneural NF1 MPNST suggests a potential association between steroid hormones and tumor cell proliferation.
Perrin GQ; Li H; Fishbein L; Thomson SA; Hwang MS; Scarborough MT; Yachnis AT; Wallace MR; Mareci TH; Muir D
Lab Invest; 2007 Nov; 87(11):1092-102. PubMed ID: 17876295
[TBL] [Abstract][Full Text] [Related]
20. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]